Skip to main content

Advertisement

SpringerLink
Log in

Treatment strategies for obesity-related hypertension

  • Clinical Trials Report
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Flegal KM, Conoll MD, Ogden CL, et al.: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727.

    Article  PubMed  Google Scholar 

  2. Scholze J, Grimm E, Herrman D, et al.: Optimal treatment of obesity-related hypertension. The Hypertension-Obesity Sibutramine (HOS) Study. Circulation 2007, 115:1991–1998.

    Article  PubMed  CAS  Google Scholar 

  3. Zhang R, Thakur V, Morse S, et al.: Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension. J Hum Hypertens 2002, 16:819–827.

    Article  PubMed  CAS  Google Scholar 

  4. Sramek JJ, Leibowitz MT, Weinstein SP, et al.: Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind randomized trial. J Hum Hypertens 2002, 16:13–19.

    Article  PubMed  CAS  Google Scholar 

  5. McMahon FG, Weinstein SP, Rouk E, et al.: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Human Hypertens 2002, 16:5–11.

    Article  CAS  Google Scholar 

  6. Reisin E, Weed SG: The treatment of obese hypertensive black women: a comparative study of chlorthodone versus clonidine. J Hypertension 1992, 10:489–493.

    Article  CAS  Google Scholar 

  7. White WB, Elliot WJ, Johnson MF: Chronotherapeutic delivery of verapamil in obese versus nonobese patients with essential hypertension. J Human Hypertens 2001, 15:138–141.

    Google Scholar 

  8. Reisin E, Weir M, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multi-center placebo-controlled trial. Hypertension 1997, 30:140–145.

    PubMed  CAS  Google Scholar 

  9. Jordan J, Engdi S, Boye SW, et al.: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047–1055.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Efrain Reisin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reisin, E. Treatment strategies for obesity-related hypertension. Current Science Inc 10, 129–130 (2008). https://doi.org/10.1007/s11906-008-0024-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-008-0024-z

Keywords

Search

Navigation